This trial is evaluating whether routine screening will improve 1 primary outcome and 25 secondary outcomes in patients with Type 2 Diabetes Mellitus. Measurement will happen over the course of 1 day.
This trial requires 5000 total participants across 2 different treatment groups
This trial involves 2 different treatments. Routine Screening is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"There is no cure for NASH. The primary risk factor for steatohepatitis is lifestyle, and these patients must reduce their BMI. The role of the diet is not clearly defined. The use of statins could provide benefit in patients with more advanced disease. Lifestyle modification remains the most important treatment strategy." - Anonymous Online Contributor
"More than 50,000-70,000 Americans are diagnosed with NAFLD annually. NAFLD has emerged as the second most frequent cause of advanced fibrosis in the United States, after HCV." - Anonymous Online Contributor
"In a group of patients with a body mass index below 28 kg/m(2), nonalcoholic steatohepatitis was not associated with impaired fasting glucose with diabetes mellitus II, and in this group, nonalcoholic steatohepatitis should not be considered a risk factor for impaired fasting glucose. In patients with a body mass index above 28 kg/m(2) and nonalcoholic steatohepatitis, impaired fasting glucose with diabetes mellitus II should be considered a risk factor for nonalcoholic steatohepatitis." - Anonymous Online Contributor
"The signs and symptoms of steatohepatitis are similar to those of chronic hepatitis C. In a diagnosis of steatohepatitis, a biopsy will be indicated in most patients." - Anonymous Online Contributor
"In both men with and without obesity, genetic tendencies play a part in the development of NASH. This implies an active process in obesity itself. Nonalcoholic fatty liver disease is a key in the pathogenesis of NASH." - Anonymous Online Contributor
"The present study revealed that, contrary to widely held belief, no one nonalcoholic steatohepatitis drug or treatment is ideal and that there is no'standard' therapy, although there are treatments that can be used for the majority of cases." - Anonymous Online Contributor
"The majority of patients with NASH failed to maintain remission long-term, and thus, the patients should not meet a high index of certainty before the clinical trials." - Anonymous Online Contributor
"There has been a significant amount of progress over the past few decades in treatment options for NASH. Novel therapies, such as endoscopic balloon dilation/remodeling of strictured portions of the esophagus or the liver ducts, are currently in Phase 2 or 3 clinical trials. Other treatments that are being intensively researched are lipid-liver specific agents, thiazolidinediones, and more specifically PPARgamma." - Anonymous Online Contributor
"Although the screening of nonalcoholic steatohepatitis patients with a simple questionnaire is effective at detecting those with abnormal liver biochemistry, it does not significantly improve a patient's quality of life." - Anonymous Online Contributor
"The USFDA approved a more specific diagnostic algorithm in June 2015; this algorithm is no longer used in the United States. As of January 2016, the USFDA approved two additional diagnostic tests for routine use: the elastography test for jaundice to guide treatment, and the combination Hepatitis C/HIV test as part of routine screening.\n\nFindings from a recent study of a study were first published September 4, 2017 in Archives of Internal Medicine. The study, based on a database of 1.5 million U.S. hospitalizations, identified a 7-fold increase in patients hospitalized for nonalcoholic fatty liver disease (NAFLD) within a year after diagnosis of Parkinson's disease." - Anonymous Online Contributor
"Patients with known or suspected liver disease who are undergoing evaluation for suspected NAFLD often have abnormal liver tests and ultrasound findings that could indicate NAFLD and NASH. In this cohort, all patients who received any screening for liver disease were appropriately screened (biopsy in 46% of patients). None of these patients went on to have a true diagnosis of NASH with or without concurrent liver disease. Thus, the addition of a baseline ultrasound screening scan to standard laboratory testing was not associated with increased diagnostic yield." - Anonymous Online Contributor
"Routine screening of the general population with ultrasonography and magnetic resonance imaging may be more effective than a placebo intervention in the detection of asymptomatic or occult NASH." - Anonymous Online Contributor